RNAZ
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- TransCode reports continued disease stabilization and longer treatment duration with TTX-MC138 in follow-up from its ongoing Phase 1a trialSep 28, 2026
- TransCode Therapeutics announces patent advances in Australia and Japan, strengthening its global RNA-based immuno-oncology IP portfolioSep 22, 2026
- TransCode Therapeutics successfully completed its Phase 1a trial and reported safety and disease stabilization data for TTX-MC138Jun 3, 2026
- TransCode Therapeutics and Quantum Leap submitted an IND amendment for a Phase 2a clinical trial of TTX-MC138Feb 5, 2026
- TransCode Therapeutics announces acquisition of Polynoma and $25 million strategic financing by CK Life Sciences subsidiary to form unique immuno-oncology and metastatic prevention companyOct 8, 2025